Just over a year ago, the European Union and the US Food and Drug Administration approved a new anti-retroviral drug to treat human immunodeficiency virus (HIV) infections. Lenacapavir is the first drug available to patients ...
Feb 13, 2024
0
8
Epithelioid sarcoma, a rare aggressive cancer that usually strikes young adults, and rhabdoid tumors, which affect children, have long been difficult to treat. But the outlook for people with these subtypes of soft tissue ...
Feb 5, 2024
0
9
A new treatment shows promise against the deadly neurodegenerative disease ALS, a study based on mice showed Tuesday.
Jan 31, 2024
0
85
A new, systematic analysis of cancer cells identifies 370 candidate priority drug targets across 27 cancer types, including breast, lung and ovarian cancers.
Jan 11, 2024
0
10
Yale researchers have identified a drug target that may alleviate joint degeneration associated with osteoarthritis, a debilitating condition that afflicts as many as 30 million people in the United States alone, which they ...
Jan 3, 2024
0
63
Researchers at the Icahn School of Medicine at Mount Sinai have uncovered insights into the potential mechanism of action of the antipsychotic medication asenapine, a possible therapeutic target for substance use and neuropsychiatric ...
Jan 2, 2024
0
48
Cambridge scientists have grown small blood vessel-like models in the lab and used them to show how damage to the scaffolding that supports these vessels can cause them to leak, leading to conditions such as vascular dementia ...
Nov 16, 2023
0
76
Researchers have revealed a new mechanism of targeted drug treatment used against chronic lymphocytic leukemia, through the promotion of immune cell function, that could be exploited using new anti-cancer immunotherapies.
Oct 19, 2023
0
0
The scientific literature is clear: chronic stress experienced in childhood increases the risk of illness in adulthood—everything from obesity and cancer to dependence and depression.
Oct 10, 2023
0
1
Researchers at Vanderbilt-Ingram Cancer Center have discovered a drug target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.
Oct 4, 2023
0
1
